Overview

A Study of Vantictumab (OMP-18R5) in Combination With Nab-Paclitaxel and Gemcitabine in Previously Untreated Stage IV Pancreatic Cancer

Status:
Completed

Trial end date:
2017-11-01

Target enrollment:

Participant gender:

Summary

This is an open-label Phase 1b dose-escalation study to assess the safety, tolerability, and PK of vantictumab when combined with nab-paclitaxel and gemcitabine.

Phase:

Phase 1

Details

Lead Sponsor:

OncoMed Pharmaceuticals, Inc.

Treatments:

Albumin-Bound Paclitaxel
Gemcitabine
Paclitaxel